Anticancer Research: 43 (3)

March 2023; Volume 43,Issue 3

Special Issue on New Anticancer Agents

Reviews

Open Access
Lung Cancer – Standard Therapy and the Use of a Novel, Highly Effective, Well Tolerated, Treatment With Progesterone Receptor Modulators
JEROME H. CHECK, TRINA PORETTA, DIANE CHECK and MAYA SRIVASTAVA

Anticancer Research March 2023, 43 (3) 951-965; DOI: https://doi.org/10.21873/anticanres.16240
Open Access
Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies
IOANNIS A. VOUTSADAKIS and ATHINA STRAVODIMOU

Anticancer Research March 2023, 43 (3) 967-981; DOI: https://doi.org/10.21873/anticanres.16241
Open Access
The Potential Impact of New Drug and Therapeutic Modalities on Drug Resistance to Renal Cell Carcinoma
PEDRO CAETANO PINTO

Anticancer Research March 2023, 43 (3) 983-991; DOI: https://doi.org/10.21873/anticanres.16242
Open Access
Phytocannabinoids in Triple Negative Breast Cancer Treatment: Current Knowledge and Future Insights
SABRINA BIMONTE, GIUSEPPE PALMA, MARCO CASCELLA and ARTURO CUOMO

Anticancer Research March 2023, 43 (3) 993-1000; DOI: https://doi.org/10.21873/anticanres.16243

Experimental Studies

Open Access
7,8-Diacetoxy-3-(4-methylsulfonylphenyl)-4-phenylcoumarin Induces ROS-dependent Cell Death in the A549 Human Lung Cancer Cell Line
MUSILIYU A. MUSA and QUDUS KOLAWOLE

Anticancer Research March 2023, 43 (3) 1001-1007; DOI: https://doi.org/10.21873/anticanres.16244
Open Access
Cyclodextrin Conjugated α-Bisabolol Suppresses FAK Phosphorylation and Induces Apoptosis in Pancreatic Cancer
MIKIKO TAKEBAYASHI KANO, TOSHIO KOKURYO, TAISUKE BABA, KIMITOSHI YAMAZAKI, JUNPEI YAMAGUCHI, MASAKI SUNAGAWA, ATSUSHI OGURA, NOBUYUKI WATANABE, SHUNSUKE ONOE, KAZUSHI MIYATA, TAKASHI MIZUNO, KAY UEHARA, TSUYOSHI IGAMI, YUKIHIRO YOKOYAMA, TOMOKI EBATA and MASATO NAGINO

Anticancer Research March 2023, 43 (3) 1009-1016; DOI: https://doi.org/10.21873/anticanres.16245
Open Access
Plasma Rhenium and Selenium Concentrations After Repeated Daily Oral Administration of Rhenium(I)-diselenoether in 4T1 Breast Tumor-bearing Mice
PHILIPPE COLLERY, BERNHARD MICHALKE, MARIANNA LUCIO, DIDIER VARLET, JEAN-MARIE GUIGONIS, JEAN-CLAUDE SCIMECA, HEIDY SCHMID-ANTOMARCHI and ANNIE SCHMID-ALLIANA

Anticancer Research March 2023, 43 (3) 1017-1023; DOI: https://doi.org/10.21873/anticanres.16246
You have access
Epigallocatechin Gallate Inhibits Cell Growth and Hedgehog Signalling in Human Rhabdomyosarcoma Cell Lines
BENJAMIN F.B. MAYER, MATIAS J. STAGNO, JÖRG FUCHS, STEVEN W. WARMANN and EVI SCHMID

Anticancer Research March 2023, 43 (3) 1025-1030; DOI: https://doi.org/10.21873/anticanres.16247
You have access
Modulatory Activity of the Copper Chelate, Copper N-(2-Hydroxy Acetophenone) Glycinate, in ABC-transporter-expressing Cell Lines
EVA-MARIA HARTINGER, ANNE MAHRINGER, SOUMITRA KUMAR CHOUDHURI, GERT FRICKER and THOMAS EFFERTH

Anticancer Research March 2023, 43 (3) 1031-1041; DOI: https://doi.org/10.21873/anticanres.16248
You have access
Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 Inhibitors
KEITA OGAWA, TETSUHIRO CHIBA, MASATO NAKAMURA, JUN ARAI, JIAQI ZHANG, YAOJIA MA, NA QIANG, JUNJIE AO, SAE YUMITA, TAKAMASA ISHINO, MOTOYASU KAN, TERUNAO IWANAGA, MIYUKI NAKAGAWA, KISAKO FUJIWARA, TAKAFUMI SAKUMA, HIROAKI KANZAKI, KEISUKE KOROKI, YUKO KUSAKABE, KAZUFUMI KOBAYASHI, NAOYA KANOGAWA, SOICHIRO KIYONO, TAKAYUKI KONDO, RYO NAKAGAWA, SADAHISA OGASAWARA, RYOSUKE MUROYAMA, SHINGO NAKAMOTO, TATSUO KANDA, HITOSHI MARUYAMA, JUN KATO, SHOJI MATSUMOTO, TAKAYOSHI ARAI, SHINICHIRO MOTOHASHI and NAOYA KATO

Anticancer Research March 2023, 43 (3) 1043-1052; DOI: https://doi.org/10.21873/anticanres.16249
You have access
Specific Aptamer Functionalization of Dense Ceramic by Click Chemistry Towards Circulating Tumor Cells Apheresis
GUISLAINE BARRIERE, MICHEL RIGAUD, CLEMENT ARRAT, HELOÏSE COLOMBI and EVELYNE POLI

Anticancer Research March 2023, 43 (3) 1053-1064; DOI: https://doi.org/10.21873/anticanres.16250
Open Access
Atezolizumab Retains Cellular Binding to Programmed Death Ligand 1 Following Aerosolization via Mesh Nebulizer
GINTARAS ZALESKIS, MARTYNAS TALAIKIS, DAINIUS CHARACIEJUS, VINCAS URBONAS, PAULIUS BOSAS, ADAS DARINSKAS, LAVIJA ZIBUTYTE, LUKAS SIMKUS, ZILVINAS SURVILA, JURGITA JURSENAITE and MARGARITA ZVIRBLE

Anticancer Research March 2023, 43 (3) 1065-1072; DOI: https://doi.org/10.21873/anticanres.16251
You have access
Validation of EZH2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines
HIROTAKA NAKAYAMA, NAO SAITO, RIKA KASAJIMA, NOBUYASU SUGANUMA, YASUSHI RINO, KATSUHIKO MASUDO, HARUHIKO YAMAZAKI, SOJI TODA, KAZUMASA SEKIHARA, HIROYUKI IWASAKI and DAISUKE HOSHINO

Anticancer Research March 2023, 43 (3) 1073-1077; DOI: https://doi.org/10.21873/anticanres.16252
You have access
Chemokine (C-C motif) Ligand 2 Is Regulated Through the EGFR/Src Pathway in HER2-positive Breast Cancer Cells
DAEUN YOU, HYUNGJOO KIM, YISUN JEONG, SUN YOUNG YOON, EUNJI LO, JEONG EON LEE and SANGMIN KIM

Anticancer Research March 2023, 43 (3) 1079-1089; DOI: https://doi.org/10.21873/anticanres.16253
You have access
Isophysalin A Inhibits the Stemness of Breast Cancer Cells Possibly via Stat3 and IL-6 Signaling
YU-CHAN KO, HACK SUN CHOI, SU-LIM KIM and DONG-SUN LEE

Anticancer Research March 2023, 43 (3) 1091-1101; DOI: https://doi.org/10.21873/anticanres.16254
You have access
Low-dose Pimecrolimus, an FDA-approved Calcineurin Inhibitor, Sensitizes Drug-resistant Cancer Cells via Strong P-gp Inhibition
JAE HYEON PARK, JI SUN LEE, JOO KYUNG SHIN, SWATI SHARMA, HYUNG SIK KIM and SUNGPIL YOON

Anticancer Research March 2023, 43 (3) 1103-1112; DOI: https://doi.org/10.21873/anticanres.16255
You have access
5-Oxoproline Enhances 4-Hydroxytamoxifen-induced Cytotoxicity by Increasing Oxidative Stress in MCF-7 Breast Cancer Cells
TAKANOBU NADAI, KATSUYA NARUMI, YUTO MUKAI, HINATA UEDA, AYAKO FURUGEN, YOSHITAKA SAITO and MASAKI KOBAYASHI

Anticancer Research March 2023, 43 (3) 1113-1120; DOI: https://doi.org/10.21873/anticanres.16256
You have access
A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model
SHINJI KOBUCHI, MOTOI TSUDA, MAKI OKAMURA, TAKANORI NAKAMURA and YUKAKO ITO

Anticancer Research March 2023, 43 (3) 1121-1130; DOI: https://doi.org/10.21873/anticanres.16257
You have access
Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide
YURIKA NAKAGAWA-SAITO, YUTA MITOBE, KEITA TOGASHI, SHUHEI SUZUKI, ASUKA SUGAI, CHIFUMI KITANAKA and MASASHI OKADA

Anticancer Research March 2023, 43 (3) 1131-1138; DOI: https://doi.org/10.21873/anticanres.16258
You have access
Dihydroartemisinin Induced Apoptosis and Synergized With Chemotherapy in Pleural Effusion Lymphoma Cells
PLOYPLOEN PHIKULSOD, RYUSHO KARIYA, JUTATIP PANAAMPON and SEIJI OKADA

Anticancer Research March 2023, 43 (3) 1139-1148; DOI: https://doi.org/10.21873/anticanres.16259
You have access
Streptonigrin Mitigates Lung Cancer-induced Cachexia by Suppressing TCF4/TWIST1-induced PTHLH Expression
XUE-QUAN FANG, SEONGHOON LEE, YOUNG-SEON KIM, GA EUL HAN, CHANG-HOON LIM and JI-HONG LIM

Anticancer Research March 2023, 43 (3) 1149-1157; DOI: https://doi.org/10.21873/anticanres.16260
You have access
Down-regulating Effect of a Standardized Extract of Cultured Lentinula edodes mycelia on Cortactin in Prostate Cancer Cells Is Dependent on Malignant Potential
SHIN-NOSUKE YAMASHITA, YOSHIATSU TANAKA, TAKAO KITAGAWA, BYRON BARON, KAZUHIRO TOKUDA, DURGA PAUDEL, KOJI NAKAGAWA, TOHRU OHTA, JUN-ICHI HAMADA, MASANOBU KOBAYASHI, HIROKI NAGAYASU and YASUHIRO KURAMITSU

Anticancer Research March 2023, 43 (3) 1159-1166; DOI: https://doi.org/10.21873/anticanres.16261
You have access
Hinokitiol Inhibits the Viability of Oral Squamous Carcinoma Cells by Inducing Apoptosis and Autophagy
HSIN-CHIEH LIN, CHIH-CHUN WANG, CHING-FANG WU, YUAN-HO LIN, WEI-CHANG LEE, PO-JEN CHEN, YU CHANG and YU-CHIEH SU

Anticancer Research March 2023, 43 (3) 1167-1173; DOI: https://doi.org/10.21873/anticanres.16262
You have access
Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and Bladder Urothelial Carcinoma Cells
SAN-YUAN CHEN, CHUN-NUN CHAO, HSIN-YI HUANG, PEI-WEN ZHAO and CHIUNG-YAO FANG

Anticancer Research March 2023, 43 (3) 1175-1184; DOI: https://doi.org/10.21873/anticanres.16263
You have access
Oncolytic Effect of a Recombinant Vesicular Stomatitis Virus Encoding a Tumor-suppressor MicroRNA in an Osteosarcoma Mouse Model
TOMOHIKO SAKUDA, TADAHIKO KUBO, MUHAMMAD PHETRUS JOHAN, TAISUKE FURUTA, TAKEMASA SAKAGUCHI and NOBUO ADACHI

Anticancer Research March 2023, 43 (3) 1185-1191; DOI: https://doi.org/10.21873/anticanres.16264
You have access
Fluoxetine Inhibits STAT3-mediated Survival and Invasion of Osteosarcoma Cells
WEI-TING CHEN, YUAN-HSIN TSAI, PEGGY TAN, FEI-TING HSU, HUI-MIN DAVID WANG, WEI-CHIN LIN, FENG-HUEI LIN and CHING-TE WU

Anticancer Research March 2023, 43 (3) 1193-1199; DOI: https://doi.org/10.21873/anticanres.16265
You have access
Anticancer Effects of Antidepressants in Hepatocellular Carcinoma Cells
YA-HUI HUANG and CHAU-TING YEH

Anticancer Research March 2023, 43 (3) 1201-1206; DOI: https://doi.org/10.21873/anticanres.16266
You have access
Redox-mediated Anticancer Activity of Anti-parasitic Drug Fenbendazole in Triple-negative Breast Cancer Cells
SEVERINA SEMKOVA, BILIANA NIKOLOVA, IANA TSONEVA, GEORGI ANTOV, DONIKA IVANOVA, ANTON ANGELOV, ZHIVKO ZHELEV and RUMIANA BAKALOVA

Anticancer Research March 2023, 43 (3) 1207-1212; DOI: https://doi.org/10.21873/anticanres.16267
You have access
Docosahexaenoic Acid Potentiates the Anticancer Effect of the Menadione/Ascorbate Redox Couple by Increasing Mitochondrial Superoxide and Accelerating ATP Depletion
DONIKA IVANOVA, SEVERINA SEMKOVA, ZVEZDELINA YANEVA, BILIANA NIKOLOVA, ZHIVKO ZHELEV, RUMIANA BAKALOVA and ICHIO AOKI

Anticancer Research March 2023, 43 (3) 1213-1220; DOI: https://doi.org/10.21873/anticanres.16268
You have access
Gene Profiling of Cannabis-sativa-mediated Apoptosis in Human Melanoma Cells
KANITA POOMMARAPAN, PAISAL RUMMANEETHORN, ATTASIT SRISUBAT, NUNTAKAN SUWANPIDOKKUL, PETCHPAILIN LEENUTAPHONG, THAMTHIWAT NARARATWANCHAI, SIRADA SRIHIRUN, WANTHANEE PHETCHENGKAO, KANKANIT SURIYACHAN and SALUNYA TANCHAROEN

Anticancer Research March 2023, 43 (3) 1221-1237; DOI: https://doi.org/10.21873/anticanres.16269
You have access
A Standardized Extract of Cultured Lentinula edodes mycelia Up-regulates COX-2 in Inflammation-related Malignant Progressive Fibrosarcoma Cell Clone QRsP-11
TAKAO KITAGAWA, SHAJEDUL ISLAM, BYRON BARON, KAZUHIRO TOKUDA, DURGA PAUDEL, TOHRU OHTA, KOJI NAKAGAWA, MASANOBU KOBAYASHI, FUTOSHI OKADA and YASUHIRO KURAMITSU

Anticancer Research March 2023, 43 (3) 1239-1244; DOI: https://doi.org/10.21873/anticanres.16270
You have access
Aurelianolides from Aureliana fasciculata var. fasciculata Trigger Apoptosis With Caspase Activation in Human Leukemia Cells
GUSTAVO WERNECK DE SOUZA E SILVA, ANDRÉ MESQUITA MARQUES, ANA PAULA GREGÓRIO ALVES FONTÃO, SIMONE CRISTINA DE MOURA LIMA, MARIA AUXILIADORA COELHO KAPLAN, MARIA RAQUEL FIGUEIREDO and ANDRÉ LUIZ FRANCO SAMPAIO

Anticancer Research March 2023, 43 (3) 1245-1253; DOI: https://doi.org/10.21873/anticanres.16271
Open Access
Efficacy of Multimodality Approach in Patients With Recurrent Head and Neck Squamous Cell Carcinoma
PASCALE ALICIA HOELL, KHALED ELSAYAD, HENDRIK BERSSENBRUEGGE, DOMINIK HERING, CHRISTOPHER KITTEL, JOHANNES KLEINHEINZ, ANNALEN BLECKMANN, GEORG EVERS, EVA WARDELMANN, CLAUDIA RUDACK and HANS THEODOR EICH

Anticancer Research March 2023, 43 (3) 1255-1263; DOI: https://doi.org/10.21873/anticanres.16272

Clinical Studies

Open Access
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
MARINA ABE, TADAHIRO SHOJI, YOHEI CHIBA, ERIKO TAKATORI, YOSHITAKA KAIDO, TAKAYUKI NAGASAWA, MASAHIRO KAGABU, FUMIAKI TAKAHASHI, TAKESHI AIDA and TSUKASA BABA

Anticancer Research March 2023, 43 (3) 1265-1272; DOI: https://doi.org/10.21873/anticanres.16273
Open Access
Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
SANDRO M. WAGNER, TERESA MAGNES, THOMAS MELCHARDT, DOMINIK KIEM, LUKAS WEISS, DANIEL NEUREITER, CHRISTINA WAGNER, MARIE-BERNADETTE ARETIN, STEFAN NEMEC, GABRIELE GAMERITH, GEORG PALL, RICHARD GREIL and THORSTEN FUEREDER

Anticancer Research March 2023, 43 (3) 1273-1282; DOI: https://doi.org/10.21873/anticanres.16274
You have access
Effects of ABCB1 and ABCG2 Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18)
AKIMITSU MAEDA, HITOSHI ANDO, KEI IRIE, NAOYA HASHIMOTO, JUN-ICHI MORISHIGE, SHOJI FUKUSHIMA, HIROMICHI EBI, KOSAKU UCHIDA, HIROJI IWATA and MASATAKA SAWAKI

Anticancer Research March 2023, 43 (3) 1283-1289; DOI: https://doi.org/10.21873/anticanres.16275
You have access
Abemaciclib-associated Diarrhea: An Exploratory Analysis of Real-life Data
VITTORIO GEBBIA, FEDERICA MARTORANA, MARIA VITA SANÒ, MARIA ROSARIA VALERIO, FRANCESCO GIOTTA, MASSIMILIANO SPADA, DARIO PIAZZA, MICHELE CARUSO and PAOLO VIGNERI

Anticancer Research March 2023, 43 (3) 1291-1299; DOI: https://doi.org/10.21873/anticanres.16276
You have access
Effect of Mirtazapine for the Prevention of Nausea and Vomiting in Patients With Thoracic Cancer Receiving Platinum-based Chemotherapy
MOTOHIKO KINOMURA, HIROTOSHI IIHARA, HIRONORI FUJII, CHIEMI HIROSE, JUNKI ENDO, KOMEI YANASE, TOSHIYA INUI, DAIZO KAITO, YUKA SASAKI, TAKENOBU GOMYO, CHIZURU SAKAI-MASUDA, DAISUKE KAWAE, YU KITAMURA, MASACHIKA FUKUI, RYO KOBAYASHI, YASUSHI OHNO and AKIO SUZUKI

Anticancer Research March 2023, 43 (3) 1301-1307; DOI: https://doi.org/10.21873/anticanres.16277
You have access
Risk Factors for Muscle Loss During Neoadjuvant Therapy for Esophageal Cancer
DAISUKE SHIMIZU, KAZUSHI MIYATA, MASAHIDE FUKAYA, SHIZUKI SUGITA and TOMOKI EBATA

Anticancer Research March 2023, 43 (3) 1309-1315; DOI: https://doi.org/10.21873/anticanres.16278
You have access
ALBI Grade Is a Predictive Factor of Lenvatinib Treatment Discontinuation due to Adverse Events in Hepatocellular Carcinoma
DAICHI ENOMOTO, KAZUHIRO YAMAMOTO, YUKI MATSUMOTO, ASAMI MORIOKA, TOMOHIRO OMURA, SHOHEI KOMATSU, YOSHIHIKO YANO, TAKUMI FUKUMOTO and IKUKO YANO

Anticancer Research March 2023, 43 (3) 1317-1323; DOI: https://doi.org/10.21873/anticanres.16279
You have access
Bevacizumab Plus Carboplatin Plus Nab-paclitaxel for Non-squamous Non-small Cell Lung Cancer in a Real-world Setting
AKIHIRO TAMIYA, MOTOHIRO TAMIYA, YUJI INAGAKI, YOSHIHIKO TANIGUCHI, KEIKO NAKAO, YOSHINOBU MATSUDA, TAKAHISA KAWAMURA, KEI KUNIMASA, TAKAKO INOUE, KAZUMI NISHINO and KYOICHI OKISHIO

Anticancer Research March 2023, 43 (3) 1325-1330; DOI: https://doi.org/10.21873/anticanres.16280
You have access
First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study
JIAN-RI LI, SHIAN-SHIANG WANG, KEVIN LU, CHAUN-SHU CHEN, CHEN-LI CHENG, SHENG-CHUN HUNG, KUN-YUAN CHIU, CHIANN YI HSU and CHENG-KUANG YANG

Anticancer Research March 2023, 43 (3) 1331-1339; DOI: https://doi.org/10.21873/anticanres.16281
You have access
Impact of Concomitant Use of Azoles on Bortezomib-related Adverse Drug Reactions Using JADER
TAKUYA IMATOH, TAICHI MATSUMOTO, YUTAKA HARAMAKI and KEISUKE MIGITA

Anticancer Research March 2023, 43 (3) 1341-1349; DOI: https://doi.org/10.21873/anticanres.16282
You have access
Is it Necessary to Treat all Metastatic Prostate Cancer With Upfront Androgen Receptor Axis-targeted Agents?
RYUNOSUKE NAKAGAWA, HIROAKI IWAMOTO, RENATO NAITO, SUGURU KADOMOTO, HIROSHI YAEGASHI, SHOHEI KAWAGUCHI, TAKAHIRO NOHARA, KAZUYOSHI SHIGEHARA, KOUJI IZUMI, YOSHIFUMI KADONO and ATSUSHI MIZOKAMI

Anticancer Research March 2023, 43 (3) 1351-1359; DOI: https://doi.org/10.21873/anticanres.16283
You have access
Combination of Lenvatinib and Proton Beam Therapy in the Management of Patients With Advanced Hepatocellular Carcinoma
JEN-YU CHENG, BING-SHEN HUANG, YEN-YANG CHEN, CHIH-CHI WANG and YEN-HAO CHEN

Anticancer Research March 2023, 43 (3) 1361-1371; DOI: https://doi.org/10.21873/anticanres.16284
You have access
Half Dose Pegfilgrastim for Patients With Breast Cancer During Chemotherapy: A Case-series
MAKO IKEDA, YUKI KATAOKA, TOMOE TAJI, HIROFUMI SUWA and HIDEKO NAKAGOSHI

Anticancer Research March 2023, 43 (3) 1373-1375; DOI: https://doi.org/10.21873/anticanres.16285
You have access
Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
YEN-HAO CHEN, YEN-YANG CHEN, JING-HOUNG WANG and CHAO-HUNG HUNG

Anticancer Research March 2023, 43 (3) 1377-1384; DOI: https://doi.org/10.21873/anticanres.16286

Corrigenda

Open Access
Corrigenda
Anticancer Research March 2023, 43 (3) 1385;

Main menu

User menu

Search

Table of Contents

Special Issue on New Anticancer Agents

Reviews

Experimental Studies

Clinical Studies

Corrigenda

In this issue

Issue highlights

Jump to